Sarcopenia and Muscle Aging: A Brief Overview.

Endocrinology and metabolism (Seoul, Korea) Pub Date : 2020-12-01 Epub Date: 2020-12-23 DOI:10.3803/EnM.2020.405
Tam Dao, Alexander E Green, Yun A Kim, Sung-Jin Bae, Ki-Tae Ha, Karim Gariani, Mi-Ra Lee, Keir J Menzies, Dongryeol Ryu
{"title":"Sarcopenia and Muscle Aging: A Brief Overview.","authors":"Tam Dao,&nbsp;Alexander E Green,&nbsp;Yun A Kim,&nbsp;Sung-Jin Bae,&nbsp;Ki-Tae Ha,&nbsp;Karim Gariani,&nbsp;Mi-Ra Lee,&nbsp;Keir J Menzies,&nbsp;Dongryeol Ryu","doi":"10.3803/EnM.2020.405","DOIUrl":null,"url":null,"abstract":"<p><p>The world is facing the new challenges of an aging population, and understanding the process of aging has therefore become one of the most important global concerns. Sarcopenia is a condition which is defined by the gradual loss of skeletal muscle mass and function with age. In research and clinical practice, sarcopenia is recognized as a component of geriatric disease and is a current target for drug development. In this review we define this condition and provide an overview of current therapeutic approaches. We further highlight recent findings that describe key pathophysiological phenotypes of this condition, including alterations in muscle fiber types, mitochondrial function, nicotinamide adenine dinucleotide (NAD+) metabolism, myokines, and gut microbiota, in aged muscle compared to young muscle or healthy aged muscle. The last part of this review examines new therapeutic avenues for promising treatment targets. There is still no accepted therapy for sarcopenia in humans. Here we provide a brief review of the current state of research derived from various mouse models or human samples that provide novel routes for the development of effective therapeutics to maintain muscle health during aging.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":"716-732"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/a4/enm-2020-405.PMC7803599.pdf","citationCount":"62","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology and metabolism (Seoul, Korea)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3803/EnM.2020.405","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/12/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 62

Abstract

The world is facing the new challenges of an aging population, and understanding the process of aging has therefore become one of the most important global concerns. Sarcopenia is a condition which is defined by the gradual loss of skeletal muscle mass and function with age. In research and clinical practice, sarcopenia is recognized as a component of geriatric disease and is a current target for drug development. In this review we define this condition and provide an overview of current therapeutic approaches. We further highlight recent findings that describe key pathophysiological phenotypes of this condition, including alterations in muscle fiber types, mitochondrial function, nicotinamide adenine dinucleotide (NAD+) metabolism, myokines, and gut microbiota, in aged muscle compared to young muscle or healthy aged muscle. The last part of this review examines new therapeutic avenues for promising treatment targets. There is still no accepted therapy for sarcopenia in humans. Here we provide a brief review of the current state of research derived from various mouse models or human samples that provide novel routes for the development of effective therapeutics to maintain muscle health during aging.

Abstract Image

Abstract Image

肌肉减少症和肌肉老化:简要概述。
世界正面临着人口老龄化的新挑战,因此了解老龄化的过程已成为全球关注的最重要问题之一。骨骼肌减少症是一种骨骼肌质量和功能随着年龄的增长而逐渐丧失的疾病。在研究和临床实践中,肌肉减少症被认为是老年病的一个组成部分,也是目前药物开发的目标。在这篇综述中,我们定义了这种情况,并提供了当前治疗方法的概述。我们进一步强调了与年轻肌肉或健康老年肌肉相比,老年肌肉中描述这种疾病的关键病理生理表型的最新发现,包括肌纤维类型、线粒体功能、烟酰胺腺嘌呤二核苷酸(NAD+)代谢、肌因子和肠道微生物群的改变。本综述的最后一部分探讨了有希望的治疗靶点的新治疗途径。目前还没有公认的治疗人类肌肉减少症的方法。在这里,我们简要回顾了各种小鼠模型或人类样本的研究现状,这些研究为开发有效的治疗方法来维持衰老期间的肌肉健康提供了新的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信